Lipocine : U.S. Court Postpones Clarus Patent Litigation Trial Scheduled

Lipocine Inc. (LPCN) said that the U.S. District Court of Delaware has postponed the February 8, 2021 jury trial scheduled to hear arguments in patent infringement lawsuit against Clarus Therapeutics, due to the ongoing effects of the COVID-19 pandemic.

The jury trial will be rescheduled once it becomes clear when jury trials will resume in the District of Delaware.

Lipocine is alleging that Clarus's JATENZO product infringes Lipocine's U.S. patents.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
Follow RTT